

Anlotinib Dihydrochloride

Catalog No: tcsc0040093



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1360460-82-7

Formula:

$C_{23}H_{24}Cl_2FN_3O_3$

Pathway:

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

Target:

VEGFR;PDGFR;c-Kit

Purity / Grade:

>98%

Solubility:

DMSO

Alternative Names:

AL3818 Dihydrochloride

Observed Molecular Weight:

480.36


Product Description

Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit **VEGFR2/3**, **FGFR1-4**, **PDGFR α/β** , **c-Kit**, and **Ret**.

IC₅₀ & Target: VEGFR2/3, FGFR1-4, PDGFR α/β , c-Kit, Ret^[1]

In Vitro: Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β , c-Kit, and Ret^[1]. The EC cell lines show differential sensitivity to Anlotinib Dihydrochloride (AL3818); AN3CA cells appear the most sensitive with an IC₅₀ value of 84 nM. The other cell lines are approximately 28- to 550-fold less sensitive to Anlotinib Dihydrochloride. HEC1B cells have an IC₅₀ value of 46 μ M, and MFE296 cells are sensitive to Anlotinib Dihydrochloride, with an IC₅₀ value of 2.9 μ M compare with 3.2, 28.9, 29, and 40 μ M for Ishikawa, MFE280, KLE, and HEC1A, respectively^[2].

In Vivo: Within the Anlotinib Dihydrochloride (AL3818)-treated (5 mg/kg) group (n=11), tumor size is found to be reduced 26-fold, with an average tumor volume of 164.8 ± 70 mm³, when compare with the control group. Following treatment with Anlotinib Dihydrochloride, only 5 of the 11 mice are found to have residual tumor burden at the end of the treatment period. Treatment with Anlotinib Dihydrochloride decreases neoangiogenesis by 48.5% and cell proliferation by 27% when compare with the control group^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!